Literature DB >> 9731824

Positron emission tomography in diagnosis of occult adenocarcinoma of the breast.

E F Block1, M A Meyer.   

Abstract

Occult adenocarcinoma with clinically apparent axillary lymphadenopathy represents a challenging surgical problem. Mammography is frequently unable to identify a primary breast carcinoma, and extramammary sources are common and equally difficult to identify. This may leave the clinician and patient with a conundrum of whether to proceed with "blind" mastectomy. A 35-year-old white female presented with axillary adenopathy and a normal breast physical exam. Mammography was unable to demonstrate a specific tumor. Excisional biopsy of the axillary lymph node demonstrated metastatic adenocarcinoma. Positron emission tomography showed increased uptake in the breast and the axilla, consistent with breast carcinoma and axillary metastases. The patient underwent modified radical mastectomy and pathologic review of the specimen proved infiltrating ductal carcinoma in the breast with metastatic nodes. Positron emission tomography may be helpful in localizing occult carcinoma of the breast that presents with metastatic lymph nodes and in excluding other potential primaries.

Entities:  

Mesh:

Year:  1998        PMID: 9731824

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  3 in total

1.  Carcinoma of Unknown Primary - an Orphan Disease?

Authors:  Alwin Krämer; Gerdt Hübner; Andreas Schneeweiss; Gunnar Folprecht; Kai Neben
Journal:  Breast Care (Basel)       Date:  2008-06-19       Impact factor: 2.860

2.  Hypermetabolic Axillary Mass on (18)F FDG PET/CT: Breast Cancer Arising from Accessory Breast Tissue.

Authors:  Ji Sun Park; Ah Young Lee; Sang Gyun Bae; Seok Mo Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-09-30

3.  Radiotherapeutic use of 2-deoxy-2-[18F]fluoro-D-glucose--a comment.

Authors:  Michael Andrew Meyer
Journal:  Breast Cancer Res       Date:  2004       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.